Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.59 |
| ▸ | CA1 | P00915 | 10/20 | 0.44 |
| ▸ | CA2 | P00918 | 10/20 | 0.44 |
| ▸ | CA9 | Q16790 | 7/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30307782 | 0.90 | PTGES2 (0.64) | PTGES2CA1CA2CA9CDK2 | |
| SCHEMBL789494 | 0.90 | PTGES2 (0.64) | PTGES2CA1CA2CA9CDK2 | |
| Hydrochloric Acid SCHEMBL27951072 | 0.88 | PTGES2 (0.62) | PTGES2CA1CA2CA9CDK2 | |
| Hydrochloric Acid SCHEMBL9955460 | 0.88 | PTGES2 (0.62) | PTGES2CA1CA2CA9CDK2 | |
| Bromide SCHEMBL14247186 | 0.88 | PTGES2 (0.62) | PTGES2CA1CA2CA9CDK2 | |
| Hydrochloric Acid SCHEMBL29969652 | 0.88 | PTGES2 (0.62) | PTGES2CA1CA2CA9CDK2 | |
| Formic Acid SCHEMBL14247387 | 0.85 | PTGES2 (0.55) | PTGES2CA1CA2CA9CDK2 | |
| Trifluoroacetic Acid SCHEMBL25391051 | 0.81 | PTGES2 (0.51) | PTGES2CA1CA2CA9CDK2 | |
| SCHEMBL775432 | 0.78 | PTGES2 (0.46) | PTGES2AKR1B1 | |
| SCHEMBL229902 | 0.78 | PTGES2 (0.46) | PTGES2CDK2AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106029074-A | Combinations of trametinib, panitumumab and dabrafenib for the treatment of cancer | 诺华股份有限公司 | 2016-10-12 | — | — | CN | claimed |
| CN-104812391-A | Combination | GLAXOSMITHKLINE LLC | 2015-07-29 | — | — | CN | claimed |
| US-20190298826-A1 | COMBINATION THERAPIES FOR CANCER | MERCK SHARP & DOHME (US) | 2019-10-03 | — | — | US | disclosed |
| EP-3355886-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | Novartis AG (CH) | 2018-08-08 | — | — | EP | disclosed |
| US-10010608-B2 | Combination therapies for cancer | MERCK SHARP & DOHME CORP. (US) | 2018-07-03 | — | — | US | disclosed |
| WO-2017037573-A1 | PHARMACEUTICAL COMBINATION COMPRISING THE PI3K INHIBITOR ALPELISIB AND THE B-RAF INHIBITOR DABRAFENIB; THE USE OF SUCH COMBINATION IN THE TREATMENT OR PREVENTION OF CANCER | NOVARTIS AG (CH) | 2017-03-09 | — | — | WO | disclosed |
| US-20160367662-A1 | COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-12-22 | — | — | US | disclosed |
| US-20160243118-A1 | COMBINATION OF BRAF AND VEGF INHIBITORS | NOVARTIS AG (CH) | 2016-08-25 | — | — | US | disclosed |
| US-9402846-B2 | Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160106835-A1 | COMBINATION THERAPIES FOR CANCER | MERCK SHARP & DOHME CORP. (US) | 2016-04-21 | — | — | US | disclosed |
| US-20160089434-A1 | COMBINATIONS OF AN ANTI-PD-L1 ANTIBODY AND A MEK INHIBITOR AND/OR A BRAF INHIBITOR | GLAXOSMITH INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-03-31 | — | — | US | disclosed |
| EP-2616057-A2 | COMBINATION OF BRAF AND VEGF INHIBITORS | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2013-07-24 | — | — | EP | disclosed |
| US-20130172378-A1 | Combination of BRAF and VEGF Inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-07-04 | — | — | US | disclosed |
| US-20120202835-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120196879-A1 | Pharmaceutical Combination of MEK Inhibitor and B-RAF Inhibitors | NOVARTIS PHARMACEUTICALS CORPORATION | 2012-08-02 | — | — | US | disclosed |
| US-20120196886-A1 | COMBINATION | GLAXOSMITHKLINE LLC (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2012068468-A1 | METHOD OF TREATMENT WITH BRAF INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2012-05-24 | — | — | WO | disclosed |
| WO-2012036919-A2 | COMBINATION OF BRAF AND VEGF INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-22 | — | — | WO | disclosed |
| EP-2282636-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190298826-A1 | COMBINATION THERAPIES FOR CANCER | BRAF, RAF1, PDCD1 | PTGES2 3746/4885CA1 4218/4885CA2 2127/4885 |
| US-20120202835-A1 | COMBINATION | PAICS, FOLH1, DHFR | PTGES2 2284/4885CA1 720/4885CA2 110/4885 |
| US-20120196879-A1 | Pharmaceutical Combination of MEK Inhibitor and B-RAF Inhibitors | BRAF, RAF1, ARAF | PTGES2 3863/4885CA1 3525/4885CA2 1125/4885 |
| US-20160089434-A1 | COMBINATIONS OF AN ANTI-PD-L1 ANTIBODY AND A MEK INHIBITOR AND/OR A BRAF INHIBITOR | BRAF, RAF1, PDCD1 | PTGES2 4563/4885CA1 3060/4885CA2 2024/4885 |
| US-20130172378-A1 | Combination of BRAF and VEGF Inhibitors | BRAF, KDR, RAF1 | PTGES2 3728/4885CA1 4608/4885CA2 1897/4885 |
| US-10010608-B2 | Combination therapies for cancer | BRAF, RAF1, PDCD1 | PTGES2 3805/4885CA1 4190/4885CA2 2091/4885 |
| US-20120196886-A1 | COMBINATION | PAICS, FOLH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PTGES2 2761/4885CA1 695/4885CA2 111/4885 |
| US-20160367662-A1 | COMBINATIONS OF TRAMETINIB, PANITUMUMAB AND DABRAFENIB FOR THE TREATMENT OF CANCER | BRAF, KRAS, RAF1 | PTGES2 3826/4885CA1 2958/4885CA2 1218/4885 |
| US-20160243118-A1 | COMBINATION OF BRAF AND VEGF INHIBITORS | BRAF, KDR, RAF1 | PTGES2 3705/4885CA1 4602/4885CA2 1888/4885 |
| US-20160106835-A1 | COMBINATION THERAPIES FOR CANCER | BRAF, RAF1, PDCD1 | PTGES2 3805/4885CA1 4190/4885CA2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.